ALK and cancer: Therefore, ALK and IGF-1R are independent drug targets according to the criterion developed by Bozic and Nowak19,20 in their models of drug combination to overcome cancer resistance, and our results are consistent with their proposal that combination therapy will be more effective than monotherapy.